Skip to content

Climb Bio, Inc. CLYM Operating Lease Right-of-Use Assets in Other Assets

Operating Lease Right-of-Use Assets in Other Assets at other companies

Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
Jade Biosciences, Inc. Common Stock logo
Jade Biosciences, Inc. Common StockJBIO
Artiva Biotherapeutics, Inc. logo
Artiva Biotherapeutics, Inc.ARTV
Alumis Inc. logo
Alumis Inc.ALMS
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH

Other financials

Income statement

See full
Operating income-$15.2M+33.9%
Net income-$13.7M+34.0%
EPS (diluted)-$0.20+35.5%

Balance sheet

See full
Cash & equivalents$8.4M-71.2%
Total debt$479.0K+1.1%
Total equity$148.1M-23.4%
Total assets$152.4M-24.1%

Cash flow

See full
Operating cash flow-$14.4M+6.8%
CapEx$109.0K
Free cash flow-$15.6M-183%

Valuation

See full
Market cap$724.95M+787%
Enterprise value$717.07M+1,247%

Returns & leverage

See full
Return on equity-30.9%-10.3pp
Debt / equity0.0×
Current ratio27.9×+13.6×

Where this comes from

Reported directly by Climb Bio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Climb Bio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Climb Bio, Inc.'s operating lease right-of-use assets in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Climb Bio, Inc.'s operating lease right-of-use assets in other assets?
Climb Bio, Inc. (CLYM) reported operating lease right-of-use assets in other assets of $447K in Q1 2026.
How has Climb Bio, Inc.'s operating lease right-of-use assets in other assets changed year-over-year?
Climb Bio, Inc.'s operating lease right-of-use assets in other assets decreased by 0.9% year-over-year, from $451K to $447K.